leon-nanodrugs GmbH strengthens Supervisory Board with appointment of Dr Robert Becker

November 25, 2020|In News

Dr Becker brings more than 35 years of pharmaceutical industry experience to the leon-nanodrugs offer

leon-nanodrugs GmbH (‘LEON’), the Munich based nanotechnology drug development company, has announced the appointment of Dr Robert Becker as an Independent Board Member to the company’s Supervisory Board.

Dr Becker is an expert in pharmaceutical product development with a wealth of experience in process chemistry. Having held senior positions at Boehringer-Ingelheim, Eli Lilly and Company, Biogen Idec and Aptalis, Dr Becker founded Impala Pharma Consulting in 2014 to provide pharma and biotech companies, academic institutions and non-governmental organizations (NGOs) with a range of strategic services to guide products from initial concept development through to launch.

Dr Becker received his doctorate in physical chemistry from the Technical University of Munich, Germany. Over the course of his career, he has gained experience of building strategic partnerships with market-leading companies for the development of small molecule and protein formulations. He has also led the design and development of formulations across all pharmaceutical dosage forms and drug delivery systems both in Europe and the United States of America.

Dr Becker said: “I am excited to join LEON at this stage in its journey. At a time when the nanotechnology sector is going from strength to strength and new opportunities are continually being unlocked through nano, I look forward to working alongside the talented team at LEON and its’ world class network  to accelerate these opportunities for our pharmaceutical partners.”

Dr Hubert Birner Chairman of the Board and Managing Partner TVM Life Science Management GmbH, TVM Capital GmbH, said: “We are delighted to welcome Dr Becker to the LEON Supervisory Board. He brings deep insight into formulation science and strong experience of building collaborations with pharmaceutical and biotech partners to support successful product development. Together with his leadership skills, these qualities make Dr Becker an ideal fit with the LEON team, and his addition builds further momentum into our goal of realising the benefits of nano for clients and patients alike.”

About LEON

leon-nanodrugs GmbH is a Munich-based pharmatech company specializing in the development of devices for the encapsulation of genetic material and other pharmaceutical active substances into nanocarriers, such as lipid nanoparticles (LNPs). LEON builds its innovative solutions based on its proprietary FR-JET technology. Its portfolio of devices, NANOlab® for process development, and NANOme® and NANOus® for GMP aseptic manufacturing, enable faster route to clinical batches and are suitable for both individualised scales and commercial production.

LEON’s platform is aimed at enabling pharma companies, small biotech, research institutes, as well as CDMOs, to take full advantage of the significant progress being made in advanced therapies.

For general information and enquiries please email info@leon-nanodrugs.com